Krystal Biotech, Inc. (KRYS) — Financial statements
Income statement, balance sheet, and cash flow for Krystal Biotech, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 389↑33.9% | 291↑473.0% | 51 | 0.00 | 0.00 | |
| Cost of Revenue | 29↑43.4% | 20↑548.4% | 3 | 0.00 | 0.00 | |
| Gross Profit | 360↑33.2% | 270↑468.1% | 48 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 58↑8.3% | 54↑15.4% | 46↑9.3% | 42↑52.3% | 28 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00↓100.0% | 78↑92.5% | 40 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 147↑29.1% | 114↑15.5% | 98↑26.6% | 78↑92.5% | 40 | |
| Other Expenses | -6↓115.3% | 38↑200.0% | 13↓50.0% | 25 | 0.00 | |
| Operating Expenses | 199↓2.8% | 205↑30.1% | 157↑8.4% | 145↑112.7% | 68 | |
| Total Costs & Expenses | 228↑1.3% | 225↑40.1% | 160↑10.5% | 145↑112.7% | 68 | |
| Operating Results | ||||||
| Operating Income | 161↑145.5% | 66↑159.9% | -110↑24.4% | -145↓112.7% | -68 | |
| Depreciation & Amortization | 7↓2.4% | 7↑13.6% | 6↑74.6% | 3↑83.1% | 2 | |
| EBITDA | 168↑52.7% | 110↑220.4% | -91↑21.8% | -117↓76.4% | -66 | |
| EBIT | 161↑56.3% | 103↑206.1% | -97↑19.1% | -120↓76.6% | -68 | |
| Interest & Other Income | ||||||
| Net Interest Income | 28↓5.0% | 30↑31.1% | 23↑333.3% | 5↑503.2% | -1 | |
| Interest Income | 28↓5.0% | 30↑31.1% | 23↑333.3% | 5↑2550.3% | 0.20 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 1 | |
| Non-Operating Income | 0.00↑100.0% | -38↓200.0% | -13↑50.0% | -25↓12590.4% | -0.20 | |
| Other Income / Expenses | 28↓5.0% | 30↓75.8% | 123↑2248.7% | 5↑503.2% | -1 | |
| Income Before Tax | 189↑98.7% | 95↑639.4% | 13↑109.2% | -140↓101.2% | -70 | |
| Income Tax Expense | -15↓347.9% | 6↑215.4% | 2 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 205↑129.7% | 89↑715.6% | 11↑107.8% | -140↓101.2% | -70 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 205↑129.7% | 89↑715.6% | 11↑107.8% | -140↓101.2% | -70 | |
| Bottom-Line Net Income | 205↑129.7% | 89↑715.6% | 11↑107.8% | -140↓101.2% | -70 | |
| EPS (Basic) | 7.08↑126.9% | 3.12↑680.0% | 0.40↑107.3% | -5.49↓75.4% | -3.13 | |
| EPS (Diluted) | 6.84↑128.0% | 3.00↑669.2% | 0.39↑107.1% | -5.49↓75.4% | -3.13 | |
| Weighted Average Shares | 29↑1.2% | 29↑5.3% | 27↑6.5% | 25↑14.8% | 22 | |
| Weighted Average Diluted Shares | 30↑0.7% | 30↑7.2% | 28↑8.9% | 25↑14.8% | 22 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.